Abstract

A Hannes-type hand prosthesis (1) has fingers (3, 3a, 3b, 3c) provided with phalanges (31, 32) controlled in flexion and extension by a system of sliding cables (5, 5a, 5b) and pulleys (64, 65). A stopping device (100, 101, 103, 104, 105) acts upon a slider (62) supporting the pulleys (64, 65) for selectively stopping the movements of the fingers (3, 3a, 3b, 3c), so that, when the user commands the actuation of some of them, the other fingers will remain locked in the flexed or extended position, and vice versa.

IPC Classes  ?

• A61F 2/58 - ElbowsWrists
• A61F 2/50 - Prostheses not implantable in the body

Abstract

The invention relates to a prosthesis (1) for limbs of the human body, in particular the leg, actuated by means of an actuator (10) capable of both generating and collecting energy. The actuator is a linear electro-hydrostatic (EHA) one, and is more compact and efficient than traditional drives based on electro-mechanical gears. Through a suitable kinematic chain, the actuator (10) produces an angle-dependent transmission ratio. The invention also comprises a generated rotor pump (20), whose external rotor is supported by rolling means.

IPC Classes  ?

• A61F 2/60 - Artificial legs or feet or parts thereof
• A61F 2/70 - Operating or control means electrical

Abstract

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/04 - Ortho-condensed systems
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 231/16 - Halogen atoms or nitro radicals
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

An actuation device (1) comprising a threaded shaft (2) connected at one end to driving means adapted to allow the threaded shaft (2) to rotate about its longitudinal axis (a). A movable element (3) is provided with a cylindrical cavity (30) adapted to receive the threaded shaft (2), and configured so that a rotation of the threaded shaft (2) corresponds to a translation the movable element (3) along the longitudinal axis (a). The device (1) has two guiding rods (4,4′) coupled to the movable element (3) and adapted to constrain the translation of the latter along a direction parallel to the longitudinal axis (a). Element (3) comprises a first (31) and a second (32) element constrained to each other, wherein the first element (31) is coupled to the threaded shaft (2) and the second element (32) is coupled to the two guiding rods (4,4′).

IPC Classes  ?

• F16H 25/22 - Screw mechanisms with balls, rollers, or similar members between the co-operating partsElements essential to the use of such members
• F16H 25/20 - Screw mechanisms
• F16H 25/24 - Elements essential to such mechanisms, e.g. screws, nuts

Abstract

Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

A display including: a plurality of light sources that emit light beams; a plurality of optical cores having an elongated shape, each optical core having a respective first end, which is optically coupled to a corresponding light source, each optical core further being such that the light beam emitted from the corresponding light source propagates in a guided manner inside the optical core; and a screen, each optical core having a respective second end, which is optically coupled to the screen. The display further includes an optical separation element, which forms a plurality of cavities that house corresponding optical cores, each cavity and the corresponding optical core forming a corresponding waveguide. The optical separation element absorbs visible light and laterally surrounds at least the first end of each optical core.

IPC Classes  ?

• G02B 6/06 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings formed by bundles of fibres the relative position of the fibres being the same at both ends, e.g. for transporting images
• G02B 6/08 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings formed by bundles of fibres the relative position of the fibres being the same at both ends, e.g. for transporting images with fibre bundle in form of plate
• G02B 6/42 - Coupling light guides with opto-electronic elements
• H01L 33/58 - Optical field-shaping elements
• F21V 8/00 - Use of light guides, e.g. fibre optic devices, in lighting devices or systems
• G02F 1/13357 - Illuminating devices
• G06F 1/16 - Constructional details or arrangements
• H01L 27/15 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components with at least one potential-jump barrier or surface barrier, specially adapted for light emission
• H01L 25/075 - Assemblies consisting of a plurality of individual semiconductor or other solid-state devices all the devices being of a type provided for in a single subclass of subclasses , , , , or , e.g. assemblies of rectifier diodes the devices not having separate containers the devices being of a type provided for in group

Abstract

A system for the exfoliation of a layered material is described, comprising in combination: an exfoliation station (14-22) operating on a volume of a dispersion of a layered precursor material, including a wet-jet milling device (10); and a collecting station (30, 40), located downstream of the exfoliation station (14-22), operating on a volume of a dispersion of the at least partly exfoliated material, in which the exfoliation station (14-22) and the collecting station (30, 40) are connected to each other through a fluid communication path (20) along which there are interposed flow regulating means (50) adapted to assume a first operating configuration in which the communication path (20) between the exfoliation station (14-22) and the collecting station (30, 40) is discontinued, where the exfoliation station (14-22) is adapted to subject a volume of dispersion of layered precursor material to a predetermined number of wet jet milling cycles; and a second operating configuration in which the communication path (20) between the exfoliation station (14-22) and the collecting station (30, 40) is continuous, where the exfoliation station (14-22) is adapted to convey a volume of previously milled dispersion including at least partly exfoliated material to the collecting station (30, 40) and is placed in communication with a supply chamber (12) to be fed with a further volume of a dispersion of layered precursor material that has to be exfoliated.

IPC Classes  ?

• C01B 32/19 - Preparation by exfoliation
• C01B 21/064 - Binary compounds of nitrogen with metals, with silicon, or with boron with boron
• C01G 39/06 - Sulfides
• C01G 41/00 - Compounds of tungsten
• C01B 19/00 - SeleniumTelluriumCompounds thereof
• B02C 19/06 - Jet mills
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The mechanism includes a threaded shaft extending along a longitudinal axis; a nut arranged coaxially with the threaded shaft; a plurality of rolling bearings interposed between the threaded shaft and the nut, each of the bearings comprising an outer race fixed to the nut, an inner race which is arranged coaxially with the outer race and is rotatable relative to the outer race about an axis of rotation, and a plurality of rolling members interposed between the outer race and the inner race; and a corresponding plurality of rings, each of which is fixed to the inner race of a respective bearing so as to rotate therewith about the same axis of rotation, and is interposed between the inner race of the bearing and the threaded shaft in such a manner that an inner surface of the ring is in contact with a screw thread of the threaded shaft.

IPC Classes  ?

• F16H 25/22 - Screw mechanisms with balls, rollers, or similar members between the co-operating partsElements essential to the use of such members

Abstract

Composition in the form of a shaped device, for use as a fiducial marker in tissues in the animal body, in radiotherapy and/or radiosurgery, characterized in that it comprises:—a core consisting of a colloidal dispersion of metal nanoparticles and/or oxides or metal salts having X-ray-contrast properties, where said nanoparticles are stabilized with surfactants, polymers or capping agents in a liquid vehicle, and—a polymeric casing that encapsulates the core, said device having a minimum size of not less than 500 microns and a maximum size not greater than 3000 microns.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 49/04 - X-ray contrast preparations

Abstract

The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

IPC Classes  ?

• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Abstract

The present invention relates to Compounds of Formula (I) and pharmaceutical compositions containing the same. It further relates to their use in the prevention or treatment of central nervous system diseases or disorders, in particular, cognitive, neurodegenerative or neuronal diseases or disorders.

IPC Classes  ?

• C07D 251/16 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 251/10 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.

IPC Classes  ?

• C07C 271/56 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 317/22 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton

Abstract

Laser device characterized in that it comprises, as gain medium, a film of colloidal nanocrystals of semiconductor material, wherein said nanocrystals are two-dimensional nanocrystals suitable for forming quantum wells for confinement of the charge carriers in the nanocrystals and having a biexciton gain mechanism.

IPC Classes  ?

• H01S 3/20 - Liquids
• H01S 5/347 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIBVI compounds, e.g. ZnCdSe-laser
• H01S 5/10 - Construction or shape of the optical resonator
• H01S 3/16 - Solid materials
• H01S 5/125 - Distributed Bragg reflector [DBR] lasers
• H01S 5/34 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
• H01S 5/04 - Processes or apparatus for excitation, e.g. pumping
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

Globular microstructures comprising a liquid core and a solid shell that envelops the core comprising polymeric micro- or nanofibers, preferably obtained by electrospinning, comprising a hydrophobic polymer or a mixture of hydrophobic polymer with polymers derived from cellulose or with polyacrylates; the microstructures may have a further coating of nanoparticles or polymeric coating. The microstructures have applications similar to those of “liquid marbles” with improved mechanical properties.

IPC Classes  ?

• B01J 13/04 - Making microcapsules or microballoons by physical processes, e.g. drying, spraying
• B01J 13/22 - Coating

Abstract

A system includes an excavation assembly, which in turn includes a supporting body having a perimetric edge defining a closed path. A distribution apparatus protrudes transversally relative to the perimetric edge and is movable in a guided manner on the supporting body. The distribution apparatus transversally distributes a quantity of hardenable or solidifiable material towards the outside of the perimetric edge, so as to be able to lay a plurality of axially superimposed annular layers(s) of the hardenable or solidifiable material defining a tubular structure (T) around the excavation assembly. A motor device moves the distribution apparatus on the supporting body.

IPC Classes  ?

• E21B 7/20 - Driving or forcing casings or pipes into boreholes, e.g. sinkingSimultaneously drilling and casing boreholes
• B05C 5/00 - Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work
• E21B 43/10 - Setting of casings, screens or liners in wells
• E21B 17/10 - Wear protectorsCentralising devices
• E21B 17/22 - Rods or pipes with helical structure
• B29C 67/00 - Shaping techniques not covered by groups , or
• B29C 53/78 - Winding and joining, e.g. winding spirally helically using profiled sheets or strips

Abstract

Process for producing a hydrophobic composite bioelastomer, comprising a cross-linked bioelastomer matrix in which an organic phase is dispersed, comprising the reaction of cross-linking of a hydroxyl-terminated polysiloxane with a silane coupling agent, comprising an acetoxysilane, to obtain a cross-linked polysiloxane with release of acetic acid. The reaction of cross-linking is carried out in the presence of starch to cause at least partial in situ acetylation by the acetic acid released from said starch that is incorporated in the cross-linked bioelastomer matrix.

IPC Classes  ?

• C08L 3/06 - Esters
• C08L 3/02 - StarchDegradation products thereof, e.g. dextrin
• C08L 83/04 - Polysiloxanes
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• C08K 3/36 - Silica
• C08K 5/5419 - Silicon-containing compounds containing oxygen containing at least one Si—O bond containing at least one Si—C bond
• C08K 5/57 - Organo-tin compounds
• C08L 83/00 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen, or carbon onlyCompositions of derivatives of such polymers
• C08L 83/02 - Polysilicates
• C08L 83/06 - Polysiloxanes containing silicon bound to oxygen-containing groups
• C08G 77/16 - Polysiloxanes containing silicon bound to oxygen-containing groups to hydroxy groups

Abstract

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

IPC Classes  ?

• C07D 205/085 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.

IPC Classes  ?

• A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
• C07D 239/54 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
• C07D 239/545 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 239/553 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
• C07D 239/557 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• C07D 239/60 - Three or more oxygen or sulfur atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

An intracortical-detection device including: at least one electrode that contacts a group of neurons; a first body, forming a surface that contacts a portion of a cerebral region; a first motor that moves the electrode with respect to the first body; a second motor; and a second body, operatively connected to the second motor, the first and second bodies being able to slide with respect to one another in a first direction, under the action of the second motor. The detection device moreover includes a sensor generating an electrical signal indicating a pressure exerted by the portion of cerebral region on the surface.

IPC Classes  ?

• A61B 18/04 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
• A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
• A61N 1/00 - ElectrotherapyCircuits therefor
• A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis

Abstract

The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). The present invention also sets forth methods for inhibiting FAAH as well as methods for treating conditions such as, but not limited to, pain, inflammation, immune disorders, dermatitis, mucositis, the over reactivity of peripheral sensory neurons, neurodermatitis, and an overactive bladder. Accordingly, the invention also provides compounds, methods, and pharmaceutical compositions for treating conditions in which the selective inhibition of peripheral FAAH (as opposed to CNS FAAH) would be of benefit.

IPC Classes  ?

• C07C 271/56 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 269/02 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
• C07D 309/14 - Nitrogen atoms not forming part of a nitro radical

Abstract

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

IPC Classes  ?

• C07D 305/12 - Beta-lactones
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/365 - Lactones

Abstract

A method of producing a lasing microsource of colloidal nanocrystals. The method includes the steps of preparing a nanocrystal solution in a solvent; depositing at least a drop of the nanocrystals solution with a drop volume below 1 nl on a flat substrate; and evaporating the solvent to dryness thereby to obtain at the edge of the evaporated drop a single annular stripe including a domain wherein the nanocrystals are arranged in an ordered array, wherein the ordered nanocrystals in the domain constitute an active region capable of lasing and the radially inner and outer edges of the stripe define a resonant cavity in which the active region is inserted.

IPC Classes  ?

• H01S 3/06 - Construction or shape of active medium

Abstract

A method for the generation of a set of conflicts for model-based system diagnostics is described, with which system a plurality of sensors is associated for the observation of variables indicative of operation conditions. The method starts from generating a complete set of Analytical Redundancy Relations (ARRs) in implicit form and, for each diagnosis instance: it performs a system simulation, computing the expected values for a first subset of Analytical Redundancy Relations (D-ARRs) including the relations involving only one system observation variable; it compares the expected and observed values of the system observation variables to identify the inconsistent variables, i.e. the unsatisfied redundancy relations, indicating a fault in at least one system component; and, when discrepancies are detected, it checks the consistency of each relation belonging to a second subset of Analytical Redundancy Relations (I-ARR), comprising relations involving a plurality of system observation variables, at least one of which exhibits discrepancies between expected and observed values; therefore identifying the support set of the unsatisfied Redundancy Relations as set of system conflicts.

IPC Classes  ?

• G06F 17/50 - Computer-aided design
• G06F 9/45 - Compilation or interpretation of high level programme languages
• G06F 11/07 - Responding to the occurrence of a fault, e.g. fault tolerance